Fundraising Fox
Numab
Founded 2011 · 75 employees on LinkedIn · 8 known investors
Find your way into Numab
Sign up to see every warm intro you have to Numab
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Numab team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Numab develops multispecific antibody-based therapeutics using its proprietary λ-Cap and MATCH discovery and engineering platforms, aiming to improve on first-generation antibody therapies in potency, stability, effect duration, and safety. It maintains its own drug pipeline targeting clinically validated pathways and works with pharma and biotech partners on discovery and development.
Founders & leadership
Numab was founded in 2011 by David Urech.
Investors · 8
How we know: HBM Healthcare Investments's portfolio page · Not right? Tell us
How we know: HBM Partners's portfolio page · funding news · press coverage · Not right? Tell us
How we know: funding news · press coverage · Not right? Tell us
How we know: funding news · press coverage · Not right? Tell us
How we know: a partner's Signal profile · funding news · press coverage · Not right? Tell us
How we know: funding news · press coverage · Not right? Tell us
How we know: funding news · press coverage · Not right? Tell us
Funding
SEC filings, press & company announcements- Undisclosed amountseries C roundMay 2021Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
Frequently asked questions
- What does Numab do?
- Numab develops multispecific antibody-based therapeutics using its proprietary λ-Cap and MATCH discovery and engineering platforms, aiming to improve on first-generation antibody therapies in potency, stability, effect duration, and safety. It maintains its own drug pipeline targeting clinically validated pathways and works with pharma and biotech partners on discovery and development.
- Who founded Numab?
- Numab was founded by David Urech in 2011.
- Who are Numab's investors?
- Numab's investors include Eisai Innovation, Inc., HBM Healthcare Investments, HBM Partners, Biotechnology Value Fund, BlackRock, Forbion, Novo Holdings, RTW Investments L.P..